Setmelanotide was initially FDA-approved in 2020 for chronic weight management in individuals six years or older with obesity caused by POMC deficiency, proprotein subtilisin/kexin type 1 (PCSK1), or LEPR deficiency [46]. The gene discussed is LEPR; the disease is hyperinsulinemic hypoglycemia, familial, 4.